+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Pipeline Insight, 2021

  • ID: 5240451
  • Drug Pipelines
  • February 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Can-Fite Biopharma
  • MORE
This “Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Advanced Hepatocellular Carcinoma with CPB liver cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Understanding

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis: Overview

Hepatocellular carcinoma is a common type of liver cancer and mostly occurs in individuals with chronic liver cirrhosis caused by HBV and HVC infection. Advanced hepatocellular carcinoma with CPB liver cirrhosis is most severe form. The cancer begins in hepatocytes and is due to mutations in DNA of liver cells. Excessive alcohol consumption, non-alcoholic fatty liver disease, and other risk factors are likely to increase the chances of developing liver cancer. Signs and Symptoms can include upper abdominal pain, unexplained weight loss, nausea, jaundice, fatigue, and chalky stools.

"Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Hepatocellular Carcinoma with CPB liver cirrhosis pipeline landscape is provided which includes the disease overview and Advanced Hepatocellular Carcinoma with CPB liver cirrhosis treatment guidelines. The assessment part of the report embraces, in depth Advanced Hepatocellular Carcinoma with CPB liver cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Hepatocellular Carcinoma with CPB liver cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Hepatocellular Carcinoma with CPB liver cirrhosis R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Hepatocellular Carcinoma with CPB liver cirrhosis.
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Emerging Drugs Chapters

This segment of the Advanced Hepatocellular Carcinoma with CPB liver cirrhosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Emerging Drugs

Namodenoson: Can-Fite Biopharma

Can-Fite Biopharma’s lead drug candidate, Namodenoson, is an orally administered small molecule with high affinity for A3 adenosine receptor and selectively binds to it. The drug is currently being evaluated for hepacellular carcinoma with CPB liver cirrhosis and has demonstrated excellent safety profile in phase II clinical trials.

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Hepatocellular Carcinoma with CPB liver cirrhosis

There are approx. 3+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma with CPB liver cirrhosis. The companies which have their Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drug candidates in the most advanced stage, i.e. phase II include, Can-Fite Biophama.

Phases

The report covers around 3+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Small molecule
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Hepatocellular Carcinoma with CPB liver cirrhosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drugs.

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Report Insights
  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drugs?
  • How many Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Hepatocellular Carcinoma with CPB liver cirrhosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Hepatocellular Carcinoma with CPB liver cirrhosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Advanced Hepatocellular Carcinoma with CPB liver cirrhosis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Can-Fite Biopharma
Key Products
  • Namodenoson
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Can-Fite Biopharma
  • MORE
Introduction

Executive Summary

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Analytical Perspective

In-depth Commercial Assessment
  • Advanced Hepatocellular Carcinoma with CPB liver cirrhosis companies' collaborations, Licensing, Acquisition - Deal Value Trends
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
  • Comparative Analysis
Namodenoson: Can-Fite Biopharma
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis6
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Companies

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Products

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Unmet Needs

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Market Drivers and Barriers

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Future Perspectives and Conclusion

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Analyst Views

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Companies

Appendix

List of Tables
Table 1 Total Products for Advanced Hepatocellular Carcinoma with CPB liver cirrhosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Advanced Hepatocellular Carcinoma with CPB liver cirrhosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Can-Fite Biopharma
Note: Product cover images may vary from those shown
Adroll
adroll